DSIP vs N-Acetyl Semax
A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
DSIP
DSIP (Delta Sleep Inducing Peptide) is a nonapeptide (9 amino acids) first isolated from rabbit thalamus in 1974, initially believed to directly induce slow-wave (delta) sleep. Research has since broadened its profile considerably: it modulates the HPA axis (reducing stress-driven cortisol), influences GH and LH release, demonstrates antioxidant properties, and may have cardioprotective effects. Despite decades of research, its precise receptor system remains incompletely characterized.
Full profileN-Acetyl Semax
N-Acetyl Semax is the acetylated form of Semax — an N-terminal acetyl group added to the standard Semax heptapeptide. The modification significantly improves resistance to aminopeptidases, extending the active half-life and producing a more sustained cognitive effect at lower doses. Considered by many researchers to be the preferred form of Semax for neurotrophin upregulation and focus enhancement.
Full profile| DSIP | N-Acetyl Semax | |
|---|---|---|
| Category | Nootropic & Cognitive | Nootropic & Cognitive |
| Also known as | Delta Sleep Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu | NA-Semax, Acetyl-Semax, N-Ac-MEHFPGP |
| Evidence | Research-stage | Research-stage |
| Dosing range | 100mcg–500mcg mcg, Once daily (evening) or every other day | 100mcg–600mcg mcg, Once daily (intranasal preferred) |
| Administration | Subcutaneous injection, Intranasal, Intravenous (clinical studies) | Intranasal (preferred), Subcutaneous injection |
| Key side effects | Generally well-tolerated, Daytime drowsiness if dosed in morning, Mild headache, Altered dream quality (common) | Mild anxiety or over-stimulation at high doses, Nasal irritation (intranasal), Difficulty sleeping if dosed late in the day (more stimulating than standard Semax), Mild appetite suppression |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: DSIP — Subcutaneous injection, Intranasal, Intravenous (clinical studies); N-Acetyl Semax — Intranasal (preferred), Subcutaneous injection.
- Frequency: DSIP is typically Once daily (evening) or every other day; N-Acetyl Semax is Once daily (intranasal preferred).
- Research depth: this profile cites 3 sources for DSIP vs 2 for N-Acetyl Semax.
How each works
DSIP
DSIP does not directly trigger sleep in the simple sense originally proposed — more recent research indicates it modulates the neuroendocrine environment that facilitates sleep. Key findings: it reduces ACTH-driven cortisol elevation under stress, increases GH secretion in some models, and attenuates withdrawal severity in opioid and alcohol dependence (mechanisms unclear). DSIP demonstrates antioxidant effects and has cardioprotective properties in ischemic preconditioning models in animals. Its unique resistance to most peptidases (attributed to its unusual conformation) gives it a relatively long half-life for a nonapeptide.
N-Acetyl Semax
Acetylation of the N-terminus blocks aminopeptidase cleavage at the most vulnerable site on the Semax molecule, extending its effective duration in biological fluids. Studies comparing acetylated vs non-acetylated ACTH fragment analogs consistently show greater stability and sustained receptor engagement with acetylated forms. N-Acetyl Semax demonstrates the same core BDNF/NGF upregulating and neuroprotective profile as Semax with reported greater potency per mcg due to improved bioavailability.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.